Speciality: ENT
Description:
A warm welcome to all the medical professionals in this interesting session on Allegra M: The number 1 prescribed Fexofenadine-Montelukast (FM) brand in India.
Allegra M has emerged as the number one prescribed brand of Fexofenadine-Montelukast (FM) in India. This combination medication is widely recognized for its efficacy in managing allergic rhinitis and asthma, providing relief from symptoms like sneezing, runny nose, and wheezing. The brand's leading position underscores its popularity and trust among healthcare professionals and patients alike.
Allegra M combines Fexofenadine, a potent antihistamine, with Montelukast, a leukotriene receptor antagonist. This dual-action formula addresses multiple pathways involved in allergic reactions, making it highly effective for patients with co-existing respiratory conditions. By targeting both histamines and leukotrienes, Allegra M offers comprehensive symptom control, enhancing patient quality of life.
The widespread prescription of Allegra M reflects its clinical benefits, including rapid onset of action and sustained symptom relief. Patients report significant improvement in nasal congestion, sneezing, and bronchoconstriction, leading to better disease management and fewer exacerbations. Its well-tolerated profile also contributes to high patient adherence and satisfaction.
Therefore, get an overall knowledge of allegra M: The number 1 prescribed fexofenadine-montelukast (FM) brand in India.
See More Webinars @ Hidoc Webinars
1.
Newly identified T-cell subtype may explain treatment-resistant childhood leukemia
2.
Glioblastoma treatment breakthrough shows promise
3.
A computer-aided diagnostic system for improved detection of breast cancer.
4.
Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy
5.
Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.
1.
Liquid Biopsies in Hematology: A Window into the Disease
2.
Unleashing the Power of AI: A Systematic Review of Predictive Biomarker Discovery in Immuno-Oncology
3.
A Visual Guide to Understanding Breast Cancer Staging
4.
Exploring the Latest Treatments for Essential Thrombocythemia
5.
Innovative Marketing Strategies for Oncology Drugs: A Clinician’s Take on Digital and B2B Trends
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
3.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
4.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
5.
Navigating the Complexities of Ph Negative ALL - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation